Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343716 | 0.88 | FGFR1 (1.00) | FGFR1NPC1RAB9AHPGDLMNA | |
| SCHEMBL122653 | 0.88 | FGFR1 (1.00) | FGFR1NPC1RAB9AHPGDLMNA | |
| SCHEMBL2649378 | 0.88 | FGFR1 (0.78) | FGFR1NPC1RAB9AHPGDLMNA | |
| Hydrochloric Acid SCHEMBL7986291 | 0.87 | FGFR1 (0.97) | FGFR1NPC1RAB9AHPGDLMNA | |
| SCHEMBL23680877 | 0.86 | FGFR1 (0.76) | FGFR1HPGD | |
| SCHEMBL13002361 | 0.86 | FGFR1 (0.76) | FGFR1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL121784 | 0.86 | FGFR1 (0.75) | FGFR1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL7986426 | 0.85 | FGFR1 (1.00) | FGFR1NPC1RAB9AHPGD | |
| SCHEMBL4278983 | 0.85 | FGFR1 (0.78) | FGFR1NPC1RAB9AHPGD | |
| SCHEMBL2649598 | 0.85 | FGFR1 (0.74) | FGFR1NPC1RAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218388-B1 | THERAPY OF PROTEIN TYROSINE KINASE MEDIATED CANCER, ATHEROSCLEROSIS, RESTENOSIS, AND PSORIASIS BY ADMINISTERING BENZIMIDAZOLE DERIVATIVE | WARNER-LAMBERT COMPANY | 2001-04-17 | — | — | US | disclosed |
| US-5990146-A | TREATING PROTEIN TYROSINE KINASE MEDIATED CANCER; ANTICARCINOGENIC AGENTS; ATHEROSCLEROSIS; RESTENOSIS; PSORIASIS; ANTIPROLIFERATIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-11-23 | — | — | US | disclosed |